CA2513143A1 - Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers - Google Patents

Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers Download PDF

Info

Publication number
CA2513143A1
CA2513143A1 CA002513143A CA2513143A CA2513143A1 CA 2513143 A1 CA2513143 A1 CA 2513143A1 CA 002513143 A CA002513143 A CA 002513143A CA 2513143 A CA2513143 A CA 2513143A CA 2513143 A1 CA2513143 A1 CA 2513143A1
Authority
CA
Canada
Prior art keywords
cancer
cell
hyaluronan
composition
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002513143A
Other languages
English (en)
French (fr)
Inventor
Bryan P. Toole
Suniti Misra
Shibnath Ghatak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2513143A1 publication Critical patent/CA2513143A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002513143A 2002-07-01 2003-07-01 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers Abandoned CA2513143A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39290502P 2002-07-01 2002-07-01
US60/392,905 2002-07-01
US45376103P 2003-03-11 2003-03-11
US60/453,761 2003-03-11
PCT/US2003/020918 WO2004003545A1 (en) 2002-07-01 2003-07-01 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers

Publications (1)

Publication Number Publication Date
CA2513143A1 true CA2513143A1 (en) 2004-01-08

Family

ID=30003285

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002513143A Abandoned CA2513143A1 (en) 2002-07-01 2003-07-01 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers

Country Status (6)

Country Link
US (2) US8093217B2 (enExample)
EP (2) EP2434282A3 (enExample)
JP (2) JP5027387B2 (enExample)
AU (1) AU2003280471B2 (enExample)
CA (1) CA2513143A1 (enExample)
WO (1) WO2004003545A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272696A1 (en) * 1998-04-02 2005-12-08 Board Of Regents Of University Of Oklahoma Methods of selectively treating diseases with specific glycosaminoglycan polymers
EP2434282A3 (en) 2002-07-01 2012-08-22 Tufts University Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
US8216777B2 (en) * 2005-05-26 2012-07-10 The Johns Hopkins University Compositions and methods for the treatment or prevention of chemoresistant neoplasia
WO2008130373A2 (en) * 2006-10-03 2008-10-30 The Board Of Regents Of The University Of Oklahoma Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20100062000A1 (en) * 2006-11-21 2010-03-11 The Regents Of The University Of California Rhamm, a Co-Receptor and Its Interactions with Other Receptors in Cancer Cell Motility and the Identification of Cancer Prognitor Cell Populations
AU2007353332B2 (en) * 2006-11-21 2013-08-01 The Regents Of The University Of California Modulation of Rhamm (CD168) for selective adipose tissue development
WO2009158040A2 (en) * 2008-06-26 2009-12-30 University Of South Florida Cancer platinum resistance detection and sensitization method
CA2703532C (en) * 2010-05-10 2018-05-01 Eva Turley Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications
JP2016501866A (ja) 2012-11-25 2016-01-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 皮下脂肪生成を刺激するペプチド
AU2014293013A1 (en) * 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
US10844102B2 (en) 2014-05-28 2020-11-24 The Regents Of The University Of California Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
EP3271383A4 (en) 2015-03-20 2019-06-12 London Health Sciences Centre Research Inc. GASED PEPTIDES AND USES THEREOF
CA3023980A1 (en) 2016-05-16 2017-11-23 Checkmab S.R.L. Markers selectively deregulated in tumor-infiltrating regulatory t cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2850376B2 (ja) * 1988-08-02 1999-01-27 日産化学工業株式会社 抗癌剤薬効増強剤
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
US5902795A (en) * 1992-06-16 1999-05-11 Trustees Of Tufts College Oligosaccharides reactive with hyaluronan-binding protein and their methods of use
WO1998006837A1 (en) * 1996-08-16 1998-02-19 Yale University Phenotypic conversion of drug-resistant bacteria to drug-sensitivity
WO1999065515A2 (en) * 1998-06-15 1999-12-23 Arch Development Corporation Combination of radiotherapy and anti-angiogenic factors
HK1041209A1 (zh) 1999-01-13 2002-07-05 Meditech Research Limited 加強藥物療效的成份及方法
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
JP2004505890A (ja) * 2000-04-04 2004-02-26 ノバルティス　アクチエンゲゼルシャフト 抗新生物剤に耐性の細胞を処置する方法
ATE440618T1 (de) * 2000-06-22 2009-09-15 Univ Iowa Res Found Kombination von cpg und antikírpern gegen cd19, cd20,cd22 oder cd40 zur prävention oder behandlung von krebs.
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
EP2434282A3 (en) 2002-07-01 2012-08-22 Tufts University Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers

Also Published As

Publication number Publication date
JP2010116410A (ja) 2010-05-27
AU2003280471B2 (en) 2009-04-23
EP2434282A3 (en) 2012-08-22
US20120095277A1 (en) 2012-04-19
JP2005532373A (ja) 2005-10-27
EP1532434A1 (en) 2005-05-25
WO2004003545A1 (en) 2004-01-08
EP1532434A4 (en) 2009-05-27
EP2434282A2 (en) 2012-03-28
JP5027387B2 (ja) 2012-09-19
AU2003280471A1 (en) 2004-01-19
US8093217B2 (en) 2012-01-10
WO2004003545A9 (en) 2004-04-15
US8648047B2 (en) 2014-02-11
US20040229843A1 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
US8648047B2 (en) Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
Munshi et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity
McDonald et al. Ionizing radiation activates the Nrf2 antioxidant response
Roger et al. Voltage-gated sodium channels: new targets in cancer therapy?
Vaisitti et al. Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor
Teranishi et al. Phosphoinositide 3‐kinase inhibitor (wortmannin) inhibits pancreatic cancer cell motility and migration induced by hyaluronan in vitro and peritoneal metastasis in vivo
Wei et al. Obatoclax and LY3009120 efficiently overcome vemurafenib resistance in differentiated thyroid cancer
Cheng et al. PKR inhibits the DNA damage response, and is associated with poor survival in AML and accelerated leukemia in NHD13 mice
Keysar et al. Inhibiting translation elongation with SVC112 suppresses cancer stem cells and inhibits growth in head and neck squamous carcinoma
JP2024037896A (ja) がん組織またはがん組織に類似した組織の培養方法
Zhu et al. Sonic hedgehog promotes synovial inflammation and articular damage through p38 mitogen-activated protein kinase signaling in experimental arthritis
Kim et al. Combined inhibition of topoisomerase I and poly (ADP-ribose) polymerase: A synergistic therapeutic strategy for glioblastoma with phosphatase and tensin homolog deficiency
Fontana et al. PGC1-α-driven mitochondrial biogenesis contributes to a cancer stem cell phenotype in melanoma
Razonable et al. Stimulation of toll-like receptor 2 with bleomycin results in cellular activation and secretion of pro-inflammatory cytokines and chemokines
Kim et al. Hyaluronic acid fuels pancreatic cancer growth
Wang et al. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines
Kim et al. Suppression of tumor progression by thioredoxin-interacting protein-dependent adenosine 2B receptor degradation in a PLAG-treated Lewis lung carcinoma-1 model of non–small cell lung cancer
Ozpolat et al. Death-associated protein 5 (DAP5/p97/NAT1) contributes to retinoic acid-induced granulocytic differentiation and arsenic trioxide-induced apoptosis in acute promyelocytic leukemia
EP3760197B1 (en) Transport protein inhibitor for reducing expression of pd-1
Wong Emerging treatment combinations: integrating therapy into clinical practice
Booth et al. GZ17-6.02 kills PDX isolates of uveal melanoma
Sinha et al. Collagen gel culture of rat mammary tumor cells as an assay system for determination of therapeutic efficacy of chemotherapeutic agents
WO2016100431A1 (en) Methods for treating inflammatory arthritis
US20240226234A1 (en) Wnt5a peptides for the treatment of acute myelogenous leukemia
Hampton et al. Exploitation of sulfated glycosaminoglycan status for precision medicine of platinums in triple-negative breast cancer

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20160704